Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kempf

Showing results (391-400 of 415) with videos related to

Pageof 42
Sort By:
Journal of Medicinal Chemistry|June 10, 2005
Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitorsClarence J Maring, Vincent S Stoll, Chen Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2007
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hitBradley J Backes, Kenton Longenecker, Gregory L Hamilton, et al.
Journal of Medicinal Chemistry|March 28, 2009
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effectsDavid A Degoey, David J Grampovnik, Charles A Flentge, et al.
Theranostics|May 1, 2019
Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse SepsisAndreas von Knethen, Anne Schäfer, Laura Kuchler, et al.
The Journal of Infectious Diseases|October 15, 2013
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validationKayode K Ojo, Richard T Eastman, Ramasubbarao Vidadala, et al.
Radiation and Environmental Biophysics|January 13, 2018
Lifetime study in mice after acute low-dose ionizing radiation: a multifactorial study with special focus on cataract riskClaudia Dalke, Frauke Neff, Savneet Kaur Bains, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1998
ABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseH L Sham, D J Kempf, A Molla, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Journal of Hepatology|January 25, 2022
Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosisVerónica Prado, María Hernández-Tejero, Marcus M Mücke, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2023
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of CryptosporidiosisMatthew A Hulverson, Ryan Choi, Deborah A Schaefer, et al.
Pageof 42

Showing results (391-400 of 415) with videos related to

Sort By:
Pageof 42
Journal of Medicinal Chemistry|June 10, 2005
Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitorsClarence J Maring, Vincent S Stoll, Chen Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2007
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hitBradley J Backes, Kenton Longenecker, Gregory L Hamilton, et al.
Journal of Medicinal Chemistry|March 28, 2009
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effectsDavid A Degoey, David J Grampovnik, Charles A Flentge, et al.
Theranostics|May 1, 2019
Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse SepsisAndreas von Knethen, Anne Schäfer, Laura Kuchler, et al.
The Journal of Infectious Diseases|October 15, 2013
A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validationKayode K Ojo, Richard T Eastman, Ramasubbarao Vidadala, et al.
Radiation and Environmental Biophysics|January 13, 2018
Lifetime study in mice after acute low-dose ionizing radiation: a multifactorial study with special focus on cataract riskClaudia Dalke, Frauke Neff, Savneet Kaur Bains, et al.
Antimicrobial Agents and Chemotherapy|December 3, 1998
ABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseH L Sham, D J Kempf, A Molla, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesZhonghua Pei, Xiaofeng Li, Thomas W von Geldern, et al.
Journal of Hepatology|January 25, 2022
Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosisVerónica Prado, María Hernández-Tejero, Marcus M Mücke, et al.
Antimicrobial Agents and Chemotherapy|March 15, 2023
Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of CryptosporidiosisMatthew A Hulverson, Ryan Choi, Deborah A Schaefer, et al.
Pageof 42